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Abstract: More than 500 patients with mucopolysaccharidosis type IH (MPS IH; Hurler 
syndrome) have been treated with hematopoietic cell transplantation (HCT) throughout the 
world since the introduction of transplantation as therapy almost 30 years ago. More recently, 
the availability of recombinant α-L-iduronidase (IDUA) has resulted in the widespread treat-
ment of less severe forms of MPS I with enzyme replacement therapy (ERT). In addition, over 
50 MPS IH patients have been treated with a combination of ERT and HCT. The rationale for 
both ERT and HCT stems from the pivotal experiments performed 4 decades ago that showed 
α-L-iduronidase supplied in the environment can correct the accumulation of substrate in 
MPS I cells. Our purpose is to address the multiple applications associated with the therapeutic 
delivery of IDUA: intermittent delivery of recombinant protein (ERT), continuous adminis-
tration through cellular therapy (HCT), the use of other stem cells or, potentially, correction 
of the enzyme defect itself through gene therapy approaches. Even though gene therapy and 
non-hematopoietic stem cell approaches, have yet to be tested in a clinical setting, it is possible 
that all these approaches will in the near future be a part of a paradigm shift from unimodal to 
multimodal therapy for MPS I.
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Enzyme replacement therapy
Mucopolysaccharidoses are autosomal recessive disorders characterized by deﬁ  -
ciencies of lysosomal hydrolases needed for the step-wise catabolism of complex 
carbohydrates termed glycosaminoglycans (GAG) (Neufeld 1991). For each disease, 
the speciﬁ  c enzyme deﬁ  ciency deﬁ  nes which substrates accumulate, and the tissues 
which are primarily affected. In mucopolysaccharidosis type I (MPS I), the deﬁ  ciency 
in α-L-iduronidase (IDUA) results in lysosomal accumulation of GAG heparan and 
dermatan sulfate (Bach et al 1972). Abnormal accumulation of these GAG leads to 
progressive cellular and multi-organ dysfunction.
The clinical phenotype of children with severe (ie, complete) deﬁ  ciency of IDUA 
may be apparent at birth, but in the majority of cases these initial symptoms and 
signs may not be evident until at 6 to 8 months of age, and the diagnosis may not be 
made until some months later. Typically, the clinical ﬁ  ndings may include hepato-
splenomegaly, umbilical or inguinal hernia, evidence of cardiac disease (coronary 
artery disease or valvular abnormalities), obstructive airway disease, corneal clouding 
and retinal degeneration, chronic rhinitis and otitis, hydrocephalus, progressive 
neurocognitive deterioration, and multiple musculoskeletal abnormalities. Without 
treatment, early death is observed, usually between 5 and 10 years of age (Neufeld 
1991; Orchard et al 2007).
In addition to patients with severe MPS I described above, two other clinical syn-
dromes exist that are characterized by less severe deﬁ  ciencies of IDUA; Hurler-Scheie Biologics: Targets & Therapy 2008:2(4) 744
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syndrome with an intermediate phenotype and Scheie 
syndrome with a mild phenotype. In contrast to patients 
with Hurler syndrome, the patients with Hurler-Scheie 
and Scheie syndromes have mild or no cognitive impair-
ment. While generally the signs and symptoms of these 
more attenuated disorders occur later and are less severe 
than in patients affected with Hurler syndrome, signiﬁ  cant 
medical problems may be seen paralleling what is seen in 
the Hurler patients.
While traditionally labeled as three distinct entities, 
Hurler (frequency 1:100,000 live births), Hurler-Scheie 
(1:115,000 live births), and Scheie (1:500,000 live births) 
syndromes represent a progressive clinical continuum, with 
the three phenotypes not necessarily clearly delineated 
(Roubicek et al 1985; Scott et al 1995; Meikle et al 1999). 
This reﬂ  ects the substantial heterogeneity in the genotypes 
encountered in the IDUA gene, and may reflect other 
modifying genes affecting the severity of disease (Pastores 
et al 2007).
The IDUA gene is localized to chromosomal band 4p16.3. 
The total length of the gene is 19 kilobases and includes 
14 exons. In wild type form, it codes for 653 amino acids and 
leads to the production of a 82 kDa protein (Schuchman et al 
1984; Unger et al 1994). Many IDUA mutations are private 
but some exhibit a signiﬁ  cant bias in different populations 
(Lee-Chen et al 1999; Lee-Chen and Wang 1997; Rempel 
et al 2005). For example, approximately 70% of patients with 
European ancestry carry one of the two severe mutations, 
W402X or Q70X, yet the spectrum of the MPS I syndromes 
presents a signiﬁ  cant challenge in deﬁ  ning treatment (Scott 
et al 1992, 1993; Sugawara et al 2008).
Since the 1980s HCT has proven to be a life-saving 
measure for the severe form of MPS IH (Hobbs et al 1981; 
Orchard et al 2007). The signiﬁ  cant toxicities associated 
with HCT, however, have made its application in less 
severe forms (Hurler-Scheie and Scheie syndrome) difﬁ  cult 
to justify.
The availability of recombinant IDUA (laronidase) for 
utilization as enzyme replacement therapy (ERT) has been a 
major advancement in the ﬁ  eld. ERT has become a mainstay 
of therapy for patients with Hurler-Scheie and Scheie, the 
attenuated forms of IDUA deﬁ  ciency that do not have central 
nervous system manifestations of their disease. As the intra-
venous administration of the enzyme has been shown to not 
effectively cross the blood brain barrier, the treatment of severe 
MPS I deﬁ  ciency with enzyme replacement alone has not been 
accepted; in the Hurler population, HCT remains the standard 
of care. However, one major consequence of the success of 
ERT in MPS I has been the potential addition of ERT prior to 
transplantation in, patients with Hurler syndrome.
As a prerequisite for the human studies, the infusion of 
enzyme as therapy has been evaluated in animal models of 
MPS I (Kakkis et al 1996, 2001b; Clarke et al 1997; Ohmi 
et al 2003). Two murine models with genetically engi-
neered IDUA deﬁ  ciency, as well as feline and canine MPS 
I models, exist. Even though they are not full phenocopies 
of human disease, all mimic the human MPS I disorder bio-
chemically (increased GAG levels in tissues and in urine) 
and in the development of visceral and central nervous 
system pathology. Studies in these animal models showed 
that both accumulation of GAG and GAG-mediated patho-
logical features can be alleviated by treatment with systemic 
recombinant enzyme, and suggested that a beneﬁ  t could be 
expected by ERT in humans (Shull et al 1994; Kakkis et al 
1996, 2001b).
  The recombinant IDUA, available for clinical 
use since 2001, is a polymorphic variant of the human 
enzyme produced by recombinant DNA technology in the 
Chinese hamster ovary cell line (Kakkis et al 1994). In the 
study that deﬁ  ned the ERT ﬁ  eld, Kakkis et al (2001a) treated 
10 patients from 5 to 22 years of age with MPS I with recom-
binant human IDUA at a dose of 125,000 units per kg of 
body weight given intravenously once weekly for 52 weeks. 
The authors concluded that the therapy reduced lysosomal 
storage of GAG and ameliorated some of the clinical mani-
festations of MPS I, with effects on growth, restrictions of 
range of motion at the shoulder and elbow, and sleep apnea. 
In addition, urinary GAG, a rough measure of total body 
GAG load, decreased after 3 to 4 weeks of IDUA treatment. 
Approximately half the patients had urticaria during IDUA 
infusion, but in general the ERT was tolerated well. Impor-
tantly, serum antibodies to IDUA were detected in 4 out of 
10 patients, but this did not appear to affect the response to 
therapy (Kakkis et al 2001a). A follow-up study concluded 
that the patients continued to exhibit an improved ability to 
perform normal daily activities (Sifuentes et al 2007). As 
such, these data demonstrate in a compelling fashion an 
opportunity for long-term alteration of morbidity associated 
with the attenuated forms of MPS I.
Since that time, additional information has been provided 
in regards to the treatment of MPS I with enzyme therapy 
(Wraith 2001). Foremost among these is a placebo-controlled, 
randomized, double-blind study of Wraith et al (2004). Forty-
ﬁ  ve MPS I patients were evaluated, 22 of whom received 
0.58 mg/kg (100 units/kg) of intravenous IDUA weekly for 
26 weeks, and 23 of whom received a placebo. It was shown Biologics: Targets & Therapy 2008:2(4) 745
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that IDUA was well tolerated, and reduced urinary GAG. 
Critically, statistically signiﬁ  cant improvement was docu-
mented in the ability to perform physical tasks and in the 
respiratory capacity in the IDUA-treated group compared to 
placebo-treated patients (Wraith et al 2004).
The same group has recently published a large, multi-
national, open-label study of 20 patients with MPS I who 
were less than 5 years old (Wraith et al 2007). Consistent 
with the previous report, ERT was again shown to be well 
tolerated, with a decrease in GAG storage (as evidenced by 
decreased hepatomegaly and GAG urinary clearance), and to 
provide clinical beneﬁ  ts such as improvement in sleep apnea 
and hypopnea to patients with severe MPS I in this early age 
group. Interestingly, a more robust decrease in GAG total 
body load was observed in patients who were receiving a 
higher dose of IDUA (200 units/kg vs 100 units/kg), and 
those with low anti-IDUA antibody levels.
These observations are relevant since IDUA therapy 
may be optimal at higher doses than those currently used. 
In addition, there is a suggestion that the immunologic 
response to the drug can be a formidable barrier to both ERT 
and HCT. Therefore, a central question in MPS I therapy is 
how completely IDUA will correct the deﬁ  ciency in various 
organ systems, and how generation of anti-IDUA antibodies 
in immunocompetent hosts will impact the efﬁ  cacy of serial, 
indeed life-long, IDUA infusions.
Intuitively, one would expect that IDUA naïve (ie, 
IDUAnull MPS I/Hurler syndrome) recipients would develop 
an immune response to systemically infused enzyme. In fact, 
this has been observed in both animal and human recipients 
of recombinant enzyme (Kakkis et al 1996; Shull et al 1996; 
Turner et al 2000; Glaros et al 2002). In an effort to mini-
mize the antibody response, induction of immune tolerance 
in canine MPS I model with a regimen consisting of cyclo-
sporine and azathioprine has been tested and proven to be 
successful (Kakkis et al 2004a).
Even more relevant to human disease has been the study 
of Kakavanos et al (2003) who observed that the patients who 
had an IDUA-speciﬁ  c immune reaction initially, developed 
immune tolerance after 2 years of treatment with IDUA. 
As accumulating data indicate that almost all ERT-treated 
patients develop anti-IDUA antibodies, it is important to 
recognize that in the majority of cases IDUA-directed anti-
bodies appear to be non-neutralizing, and as such would not 
be expected to affect the active site of the enzyme on which 
the beneﬁ  cial effects of ERT depend.
Even though most available studies have demonstrated 
that ERT is generally safe and efﬁ  cacious, ultimately the 
long-term impact of ERT is unknown (Coman et al 2008). 
This is in part because of immune responses that may prove 
important over long periods of enzyme administration. It 
is also because the effects of intermittent ERT on differ-
ent tissues are likely to be heterogeneous in response to 
therapy (eg, brain, bone, and heart valves are likely to be 
more resistant to ERT), and because how these responses 
are maintained over years of therapy is unknown. Based 
on these limitations, plus the high cost of ERT, the need 
for weekly infusions over a lifetime, and the possibility of 
immune-based reactions that may complicate therapy, the 
critical question is: should cellular therapy be used alone or 
integrated as multimodal therapy with ERT to best provide 
optimal correction of IDUA deﬁ  ciency?
Cellular therapy
The rationale for HCT originated from studies of Neufeld 
et al which showed that “cross correction” of IDUAnull cells 
with externally supplied IDUA is possible ( Fratantoni et al 
1968a, b; Bach et al 1972; Neufeld 1991). IDUA secreted by 
donor cells is modiﬁ  ed by the cellular mechanisms with the 
addition of mannose-6-phosphate residue. After secretion, 
glycosylated IDUA is taken up by recipient IDUAnull cells 
via mannose-6-phosphate receptors present on the cellular 
and subcellular membranes of the recipient cells (Hasilik and 
Neufeld 1980). After internalization, the enzyme is chan-
neled into lysosomes where it takes part in degradation of 
GAG (Fischer et al 1980). Therefore, as functional IDUA is 
provided by donor cells, HCT has the ability to provide the 
enzyme in a manner akin to ERT, except on a continuous 
rather than intermittent basis.
Allogeneic stem cell transplantation for MPS I was ﬁ  rst 
performed by Hobbs et al and was quickly followed by others as 
a life-saving measure for children with severe MPS I (Hobbs 
et al 1981; Peters et al 1996, 1998a, 1998b; Vellodi et al 1997; 
Souillet et al 2003; Hansen et al 2008). Heterozygous to normal 
serum levels of IDUA are routinely achieved after HCT, and the 
progression of this debilitating disease is arrested in most, but 
not all, organ systems. Initially, only human leukocyte antigen 
(HLA) matched related donors were used in order to minimize 
the immune-related complications of  HCT, speciﬁ  cally graft-
versus-host disease (GVHD). However, as most affected chil-
dren do not have an HLA-matched related donor, we and others 
have explored the potential of alternative donor transplantation 
using unrelated HLA-matched donors or cord blood grafts. 
Over the last 3 decades, conditioning regimens, HLA typing 
techniques and the ability to identify well matched stem cell 
grafts for HCT has been improved greatly, and HCT remains Biologics: Targets & Therapy 2008:2(4) 746
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the treatment method of choice for the severe form of MPS I 
(Staba et al 2004; Boelens et al 2007; Orchard et al 2007).
Several important concerns, however, remain. First, 
graft failure has been observed in as many as one third of 
MPS I patients treated with HCT (Grewal et al 2002). In a 
large recent European study of outcomes of HCT for Hurler 
syndrome, Boelens et al (2007) reported more graft failure 
with T-cell depletion and reduced intensity conditioning, 
and less graft failure when cord blood versus bone marrow 
has been used as a graft source. This is consistent with 
ﬁ  ndings of Staba et al (2004) who reported favorable out-
comes of MPS IH (MPS I Hurler syndrome) in recipients 
of cord blood HCT. Second, the conditioning regimen has 
been an important determinant of HCT-related complications, 
which include infection, immune injury such as GVHD, or 
direct injury to tissues such as the lung from chemotherapy 
and radiation. Furthermore, late effects after HCT include 
increased risks of cancer, sterility, effects on growth, and 
chronic GVHD.
Combination therapy
Unfortunately, some complications of HCT appear more 
common in MPS IH patients. In addition to graft failure 
discussed above, respiratory difﬁ  culties have been frequently 
observed, and many MPS IH children require mechanic 
ventilation in the peri-transplant period. These complications 
include lower respiratory infections, idiopathic pulmonary 
syndrome and, one of the most difﬁ  cult complications to effec-
tively treat, pulmonary hemorrhage (Gassas et al 2003; Tolar 
et al 2008). As the upper airway is typically compromised in 
MPS IH children due to GAG deposition in oral, nasal and 
laryngeal tissues, these patients may be at greater risk for 
intubation and prolonged ventilation, which in turn increases 
the risk of multiorgan failure and poor outcome of HCT.
Thus, we and others reasoned that ERT in peri-transplant 
period has a potential to decrease GAG accumulation in lung 
and other visceral tissues prior to transplantation, which in 
turn may decrease the risk of life-threatening complica-
tions during HCT in MPS IH patients  (Tolar et al 2007; 
Cox-Brinkman et al 2006).
Among the ﬁ  rst communications of this approach was a 
multi-institutional report of 12 MPS IH recipients of combined 
therapy (ERT and HCT) by Grewal et al (2005). The median 
duration of ERT was 12 weeks before HCT and 7 weeks after 
HCT. Eight patients had complete donor engraftment and 
11 of 12 survived at a median time of follow-up of 3 months 
(1 child died of pulmonary hemorrhage). Based on these case 
studies, it was concluded that the ERT and HCT combination 
therapy is safe and feasible, but prospective studies were 
needed to further evaluate the outcomes of co-modality 
therapy (Grewal et al 2005).
The European study lead by Cox-Brinkman et al (2006) 
also observed that ERT with HCT has been well tolerated. 
Nineteen of 22 patients studied were surviving (2 patients 
died after HCT repeated for graft failure). The generation of 
anti-IDUA antibodies has not been correlated with develop-
ment of graft failure, but overall no beneﬁ  t of ERT for this 
population of patients could be documented. Thus, these 
authors concluded that only the patients in poor clinical 
condition would beneﬁ  t from ERT before HCT.
Of note, the patient group described in this study was 
heterogeneous: patients came from multiple institutions, 
were recipients of various stem cell grafts (bone mar-
row, peripheral blood stem cells, cord blood, matched 
and mismatched family donors, and unrelated donors), 
were transplanted after variable conditioning regimens 
(4 different myeloablative regimens, 1 reduced intensity 
regimen), and received a varied number of stem cell grafts 
(approximately one third received second transplants and 
about 10% received a third HCT) (Cox-Brinkman et al 
2006).
In light of this, we chose to investigate prospectively the 
combination of ERT and HCT, utilizing a single conditioning 
regimen, receiving a similar number of enzyme infusions, 
and providing consistent supportive care in a single transplant 
center (Tolar et al 2007). Seven patients were studied at a 
median age of 1.5 years at the time of myeloablative HCT. 
Before HCT, 5 had pulmonary complications (pneumonia 
with hospitalization, abnormal sleep study, reactive early 
disease, and oxygen needs), which would be expected to 
increase their risk of complex HCT-related complications 
signiﬁ  cantly. The patients were treated with either cord blood 
transplants or related-donor bone marrow. All survived and 
their outcomes appeared superior to those of patients with 
similar number of pulmonary risk factors who were treated 
with HCT alone.
Importantly, we confirmed the findings of others 
who showed that anti-IDUA antibodies (which develop 
in most if not in all of the patients) did not appear to 
compromise donor engraftment. Theoretically, it is possible 
that pre-HCT clearance of GAG by ERT from bone marrow 
stroma could make the recipients’ bone marrow niche a more 
permissive environment for the engraftment of donor cells. 
Therefore, we favor the interpretation that all patients with 
severe MPS I, regardless of their clinical condition prior 
to transplant, could beneﬁ  t from combination therapy with Biologics: Targets & Therapy 2008:2(4) 747
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ERT and HCT, and this co-modality therapy is offered to 
all families undergoing transplantation for MPS IH at our 
institution (Tolar et al 2007).
Taken together, the cumulative data reﬂ  ecting the results 
of ERT and HCT co-modality therapy indicate that it is a 
safe and effective regimen which is now gaining wide accep-
tance. Despite the apparent beneﬁ  ts of ERT + HCT therapy, 
however, little is known about its long-term efﬁ  cacy. In 
addition, there are several obstacles that hinder the advance-
ment of this approach. One is the high cost and the limited 
availability of ERT in some countries. The second relates to 
the degree of correction on a cellular level in various tissues 
achieved in a deﬁ  ned period of time prior to transplantation, 
and whether this can be correlated with long-term sustained 
beneﬁ  ts for the MPS IH patients. Thirdly and signiﬁ  cantly, 
intravenously administered IDUA does not appear to have 
the capacity to penetrate several organ systems – most 
notably brain, bone, and the heart valves. In addition, it is 
unclear at present whether the additive beneﬁ  t of ERT and 
HCT observed early after co-modality therapy will translate 
into improvement (over and above HCT itself ) of mental, 
musculoskeletal and cardiac disabilities in MPS I patients 
now surviving long term.
Brain
The major obstacle to translocation of enzyme delivered 
intravenously across the blood-brain barrier could in theory 
be overcome by infusion of IDUA into the spinal canal or 
lateral ventricles of the brain. This approach has been mod-
eled successfully in the canine model of MPS I (Kakkis 
et al 2004b, Dickson et al 2007). Based on the animal data, 
Dickson et al (Dr Dickson, pers comm, May 2008) are test-
ing intermittent intrathecal ERT in patients with attenuated 
MPS I disease to treat progressive narrowing of cervical 
spinal canal. While promising, these therapies are still in 
the early stages and, because of the dynamics of spinal cord 
compression in MPS I (Kennedy et al 1973; Kaufman et al 
1982), data documenting outcomes with intrathecal delivery 
will not be available for several years.
Even more importantly, data from canine MPS I model 
suggest that intrathecal ERT has the potential to treat 
central nervous system and mental decline in humans 
(Dickson et al 2007). Even though some treated animals 
developed meningeal inﬂ  ammation, it is encouraging that 
with improved pharmaceutical formulation the side effects 
of intrathecal administration in patients were minimal 
(Dr. Dickson, pers comm, May 2008). The experience with 
intravenous ERT has shown that, for a beneﬁ  cial effect, 
frequent administration is required; this would suggest that 
the effects of intermittently dosed intrathecal ERT will be 
also be transient, although the frequency of administration 
may be less than what is required via the intravenous route 
(Dickson et al 2007). This would of course pose difﬁ  culties 
for the life-long treatment of IDUA deﬁ  ciency in the central 
nervous system.
It is plausible that intrathecal ERT will “bridge” the time 
between diagnosis and IDUA production by donor cells in the 
brain of the recipient following donor hematopoietic engraft-
ment. The beneﬁ  ts of HCT in the brain appear to stem from 
the ability of the donor hematopoietic cells to migrate from 
systemic vessels to the brain parenchyma after HCT (Shapiro 
et al 1995; Kennedy and Abkowitz 1997; Peters et al 1998c; 
Krivit et al 1999). The cells implicated in this process are 
microglia, hematopoietic cells of monocytic lineage (Krivit 
et al 1995). The dynamics of this engraftment are not well 
understood, as it is difﬁ  cult to determine in a clinical setting. 
However, several lines of evidence indicate that after HCT, 
donor microglia home to and engraft in the brain in sufﬁ  cient 
numbers in both mice and humans to arrest the anticipated 
ongoing neurologic deterioration.
An alternative, “Trojan horse” approach to crossing 
the blood-brain barrier has been tested by Pardridge et al 
(2005a, b, c) who used fusion proteins to transport IDUA 
across blood-brain barrier via the endocytosis-exocytosis 
pathway. Similarly, we have chosen a transferrin-IDUA 
fusion gene product to provide a proof of the concept that 
transferrin receptor-mediated transcytosis across blood brain 
barrier endothelium can be used as a functionally efﬁ  cient 
pathway for an uptake of IDUA in brain cells, including 
neurons (Osborn et al 2008).
Lastly, based on the assumption that microglial engraft-
ment after HCT or intermittent IDUA intrathecal dosing both 
have sufﬁ  cient drawbacks to make them alternative strategies 
worth exploring, continuous IDUA infusion into the spinal 
ﬂ  uid by a semi-permanent pump within the central nervous 
system or externally by catheter delivery is theoretically 
feasible.
Bone
One of the most prevalent and difﬁ  cult to manage long-term 
difﬁ  culties in otherwise successfully treated Hurler patients 
include musculoskeletal manifestations from progressive 
dysostosis multiplex (Oestreich 1985; Schmidt et al 1987; 
Masterson et al 1996; Odunusi et al 1999; Weisstein et al 
2004). The patients exhibit numerous orthopedic complica-
tions despite HCT, including kyphosis, scoliosis, cervical Biologics: Targets & Therapy 2008:2(4) 748
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spine instability, genu valgum, and carpal tunnel syndrome. 
Despite full donor engraftment after “successful” HCT (Field 
et al 1994; Weisstein et al 2004; Khanna et al 2007; Taylor 
et al 2008; Polgreen et al 2008), many patients require mul-
tiple surgeries, and, as a result of the combined effect of the 
primary MPS I disease and the impact of the conditioning 
therapy on endocrine and bone functions, are affected with 
musculoskeletal limitations for the rest of their lives.
Heart
Cardiac pathology is prominent in patients with Hurler 
syndrome. While coronary artery disease and cardiomyopa-
thy appear to be treated by successful HCT (and presum-
ably ERT), heart valve abnormalities do not appear to be 
corrected by ERT or HCT, although it is possible that these 
interventions may affect progression of valvular disease 
(Renteria et al 1976; Vinallonga et al 1992; Dangel 1998; 
Braunlin et al 2003, 2006; Hirth et al 2007). Murine model 
of MPS I (Clarke et al 1997; Russell et al 1998; Ohmi et al 
2003) represents a platform for testing various interventions 
including targeted cell therapy or attenuation of thickening 
of heart valves by secondary means such as decreasing the 
GAG-mediated inﬂ  ammation (Taylor and Gallo 2006).
Gene therapy
Yet another source of investigations likely to be relevant in 
the future are data generated by gene therapy experimentation 
in animal models of MPS I (Lutzko et al 1999; Zheng et al 
2003; Ellinwood et al 2004; Hartung et al 2004; Di Domenico 
et al 2005; Kobayashi et al 2005; Liu et al 2005; Ponder and 
Haskins 2007; Traas et al 2007; Chung et al 2007; Watson 
et al 2006; Ma et al 2007). Despite signiﬁ  cant complica-
tions and side effects observed in the viral-mediated gene 
therapy clinical trials for X-linked severe combined immune 
deﬁ  ciency and chronic granulomatous disease (Baum et al 
2003; Hacein-Bey-Abina et al 2003a, b; McCormack et al 
2003; Fischer et al 2004; von Kalle et al 2004), optimism 
remains that improved viral and non-viral vectors will 
prove to be effective for delivery of enzymes such as IDUA 
in a sufﬁ  ciently high local concentration to alter the sites 
(eg, brain, bones, heart) that are not fully corrected by the 
currently available therapies. Aside from immune reactions 
to the viral proteins, most lethal complications of gene 
therapy trials were caused by disruption of gene integrity 
and regulation in the recipient. For this reason, tremendous 
amounts of research have focused on the mechanism and risk 
quantiﬁ  cation of insertional mutagenesis. The probability of 
uncovering a relatively low-frequency/high-risk side effect 
event (such as the development of leukemias occurring in the 
X-linked severe combined immune deﬁ  ciency trial) will be 
difﬁ  cult in a surrogate organism due to the prolonged latency 
of these events. Alternatively, cancer-prone animals or cell-
based assays are likely to be used to deﬁ  ne risk-beneﬁ  t ratio 
assessments prior to future viral-based clinical trials. Improved 
vector design, enabling for example gene insertion in a speciﬁ  c 
genome location, or insulation of the gene of interest from the 
rest of the genome, or gene correction by homologous recom-
bination to avoid insertional mutagenesis, would represent 
important advances in gene therapy (Porteus et al 2006).
Stem cell gene therapy
The possibility of using gene therapy to correct hematopoietic 
cells of the recipient ex vivo followed by re-infusion with 
or without conditioning therapy, would avoid the substantial 
toxicity of allogenic transplantation, including GVHD, sus-
tained immune suppression, and graft rejection. In addition, 
non-hematopoietic stem cells isolated from bone marrow 
can be corrected ex vivo and, because of their multi-lineage 
potential, could be harnessed for organ–speciﬁ  c delivery of 
IDUA-producing cells. It is of interest that donor mesen-
chymal stem cells (MSC) can home to sites of tissue injury 
(Kunter et al 2006; Prockop 2007). MSC have been shown 
to be safe in the ﬁ  rst clinical trials for treatment for GVHD 
(Le Blanc et al 2004; Aggarwal and Pittenger 2005; Le Blanc 
and Ringden 2005a, b; Prockop and Olson 2007).
The options for non-hematopoietic stem cells in therapy 
of MPS I are multiple (Muller et al 2006). First, allogenic 
MSC have been used in metachromatic leukodystrophy and 
appeared to improve nerve conduction velocities in several 
patients (Koc et al 2002). Therefore, they can perhaps be 
used as a “depot” of cells able to produce the IDUA con-
tinuously and potentially at sites other than those targeted 
by hematopoietic cells. Second, allogenic or gene-corrected 
autologous MSC can be considered as treatment of neuro-
logic, bone, and heart valve disease not readily accessible 
by freely diffusible IDUA after HCT. In theory, they could 
be infused intravenously (to correct visceral GAG storage) 
or intrathecally (to correct brain pathology). Lastly, when 
used at the time of hematopoietic cell infusion, MSC have 
a potential to improve engraftment as well as a potential to 
prevent acute GVHD, as has been shown already in patients 
with malignant disorders receiving HCT.
Summary
Multiple agents and interventions are the mainstay of therapy 
for malignancies and infectious disease, and clearly seem Biologics: Targets & Therapy 2008:2(4) 749
IDUA in MPS I
to be the future trend in treatment of enzymopathies such as 
MPS I as well. As detailed above, the multiple tools available 
to us today for IDUA delivery include delivery of protein sys-
temically and intermittently by ERT. Alternatively, enzyme 
may be delivered by a cellular approach using either allogenic 
cells producing enzyme such as HCT, or by gene therapy 
vectors to correct IDUA deﬁ  cient cells, or to overexpress the 
gene product. These strategies will be available to researchers 
and clinicians interested in deﬁ  ning more efﬁ  cacious and less 
toxic therapy for MPS I patients in the future.
We believe that the best available approach for newly 
diagnosed MPS IH patients at the current time is combina-
tion therapy of ERT and HCT. The use of ERT can prepare 
the patient for the transplant process by decreasing the GAG 
burden in the viscera, thereby providing an opportunity to limit 
the signiﬁ  cant toxic effects of HCT. This is of key importance 
since MPS IH patients with pulmonary disease are at higher 
risk for HCT complication than MPS IH children without 
pulmonary symptoms before HCT (unpublished data).
This pre-emptive attempt to decrease morbidity associ-
ated with HCT by using ERT needs to be deﬁ  ned better by 
prospective long-term and short-term quantitative metrics, 
such as urinary GAG, determination of organomegaly, 
evidence of airway obstruction, and neuropsychological 
evaluations. Organized, multi-institutional efforts spanning 
experiences and practices throughout the world will provide 
a uniﬁ  ed collection of data and evidence-based approaches, 
allowing conclusions to be drawn more expediently as greater 
numbers of patients can be evaluated (Pastores et al 2007). 
For rare disorders such as MPS I, collaborative studies will be 
important in moving the ﬁ  eld forward and achieving optimal 
outcomes for these patients and their families.
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